Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics

Whereas recent clinical studies report metastatic melanoma survival rates high as 30–50%, many tumors remain nonresponsive or become resistant to current therapeutic strategies. Analyses of The Cancer Genome Atlas (TCGA) skin cutaneous melanoma (SKCM) data set suggests that a significant fraction of...

Descripción completa

Detalles Bibliográficos
Autores principales: Cullum, Richard L., Lucas, Lauren M., Senfeld, Jared I., Piazza, John T., Neel, Logan T., Whig, Kanupriya, Zhai, Ling, Harris, Mackenzie H., Rael, Cristina C., Taylor, Darby C., Cook, Laura J., Kaufmann, David P., Mill, Christopher P., Jacobi, Megan A., Smith, Forrest T., Suto, Mark, Bostwick, Robert, Gupta, Ram B., David, Allan E., Riese, II, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773179/
https://www.ncbi.nlm.nih.gov/pubmed/33378376
http://dx.doi.org/10.1371/journal.pone.0243901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773179/
https://www.ncbi.nlm.nih.gov/pubmed/33378376
http://dx.doi.org/10.1371/journal.pone.0243901

Ejemplares similares